News

Featured news

Hologic enables maiden net free cash flow
29 April 2024

A wrap-up of Lumos’ performance this Quarter was covered by Foster Stockbroking on ListCorp today...

Lumos to exhibit at 2024 Urgent Care Convention
11 April 2024

Lumos is excited to be exhibiting at the 2024 Urgent Care Convention April 13-17...

New FebriDx® study published in peer-reviewed journal: Infectious Diseases and Clinical Microbiology
8 April 2024

Lumos is pleased to announce that respected international journal, Infectious Diseases...

All news
Quarterly | Interview with LDX CEO, Doug Ward
30 April 2024

In this video, Lumos Diagnostics CEO Doug Ward discusses the Company's recent quarterly activity statement and cash flow report...
Hologic enables maiden net free cash flow
29 April 2024

A wrap-up of Lumos’ performance this Quarter was covered by Foster Stockbroking on ListCorp today...
Lumos to exhibit at 2024 Urgent Care Convention
11 April 2024

Lumos is excited to be exhibiting at the 2024 Urgent Care Convention April 13-17...
New FebriDx® study published in peer-reviewed journal: Infectious Diseases and Clinical Microbiology
8 April 2024

Lumos is pleased to announce that respected international journal, Infectious Diseases...
Lumos Appoints Henry Schein as US Distributor for FebriDx®
12 February 2024

Lumos Diagnostics (ASX: LDX) has today announced it has signed an agreement...
CBS News | CDC warns overuse of antibiotics may cause antimicrobial-resistant infections
13 December 2023

The Center for Disease Control has warned of the dangers of antibiotic overuse, which can make...
US FDA Grants Emergency Use Authorization For ViraDx™
11 September 2023

Lumos Diagnostics (ASX: LDX) had today announced that the US Food...
USA Today | Not 'if' but 'when': Antibiotic resistance poses existential threat for modern medicine
30 July 2023

Lumos’ FebriDx test has been identified as a useful tool in the fight to ‘outsmart’ antimicrobial...
Lumos Receives US FDA Clearance for FebriDx®
3 July 2023

Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care...
Lumos Diagnostics Appoints Doug Ward As CEO
21 June 2022

Ward to lead U.S. FebriDx launch pending FDA 510(k) clearance...
Economic Evaluation of Lumos Diagnostics’ FebriDx Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually
6 October 2021

Lumos Diagnostics (ASX: LDX) has today announced that the Journal of Health Economics...

Subscribe for Lumos news

By entering your email address you are agreeing to our Privacy Policy.

Innovation at the point-of-care

2024 Lumos Diagnostics

Quick links
Engage with us